Emir Turkes

Emir Turkes

Auto-generated profile, based on publicly available information

Emir Turkes

UK Dementia Research Institute at University College London

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2026 in Science
Verified
Journal Article
Closed access
GCGerard Crowley
Gerard Crowley
MKMinjung Kim
Minjung Kim
NONathanael O’NEill
Nathanael O’NEill
ETEmir Turkes
Emir Turkes
FGFateme Ghasemi
Fateme Ghasemi
SHSoyon Hong
Soyon Hong
Complement component 1q (C1q), the initiator of the classical complement cascade, mediates synaptic elimination in development and disease, yet the triggers for its deposition on synapses remain unclear. Using in vivo chemogenetics, we demonstrate that neuronal hyperactivity induces region-specific, C1q-dependent synapse loss in the adult hippocampus. Suppressing perforant pathway hyperactivity in a mouse model of Alzheimer’s disease reduced local amyloid-β amounts and C1q deposition and partially rescued synapse loss. Combining spatial transcriptomics, live cell tracking, and super-resolution microscopy, we identified association of antibody-secreting B-lineage cells in the adult hippocampus with activity-dependent, C1q-mediated synapse loss under physiological conditions. Together, these findings link neuronal hyperactivity to C1q-mediated synapse loss in the adult brain and implicate immunoglobulins as players in this process.

30 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SFS. L. Fowler
S. L. Fowler
TBT. S. Behr
T. S. Behr
ETE. Turkes
E. Turkes
PCP. Maglio Cauhy
P. Maglio Cauhy
MFM. S. Foiani
M. S. Foiani
BRB. Ryskeldi-Falcon
B. Ryskeldi-Falcon
SUMMARY: The abnormal assembly of tau protein in neurons is the pathological hallmark of multiple neurodegenerative diseases, including Alzheimer’s disease (AD). In addition, assembled tau associates with extracellular vesicles (EVs) in the central nervous system of patients with AD, which is linked to its clearance and prion-like propagation between neurons. However, the identities of the assembled tau species and the EVs, as well as how they associate, are not known. Here, we combined quantitative mass spectrometry, cryo-electron tomography and single-particle cryo-electron microscopy to study brain EVs from AD patients. We found filaments of truncated tau enclosed within EVs enriched in endo-lysosomal proteins. We observed multiple filament interactions, including with molecules that tethered filaments to the EV limiting membrane, suggesting selective packaging. Our findings will guide studies into the molecular mechanisms of EV-mediated secretion of assembled tau and inform the targeting of EV-associated tau as potential therapeutic and biomarker strategies for AD.

20 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
GCGerard Crowley
Gerard Crowley
ETEmir Turkes
Emir Turkes
MKMinjung Kim
Minjung Kim
SSSebastiaan De Schepper
Sebastiaan De Schepper
BTBenjy J. Y. Tan
Benjy J. Y. Tan
SHSoyon Hong
Soyon Hong
C1q, the initiating protein of the classical complement cascade, mediates synapse loss in development and disease. In various mouse models of neurologic diseases, including Alzheimer’s disease, C1q, which is secreted by microglia, the brain’s resident macrophages, is found deposited on synapses in vulnerable brain regions. However, what underlies C1q deposition on synapses in the adult brain is unclear. Using in vivo chemogenetics, we demonstrate that neuronal hyperactivity acts as a trigger for region-specific deposition of C1q, which is required for activity-dependent synapse loss. Further, using spatial transcriptomics, live cell tracking, super-resolution microscopy and other molecular and cellular tools, we report a role for B lymphocyte lineage cells and immunoglobulins in the activity-dependent C1q deposition and synapse loss. Overall, our work suggests a link between neuronal hyperactivity and C1q-mediated synapse loss in the adult brain and introduces immunoglobulins as players in this process.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
ETEmir Turkes
Emir Turkes
KDKaren E Duff
Karen E Duff
Background: Expression datasets, such as those from RNAseq and mass‐spec platforms, have been growing at an everincreasing rate and are relevant to a wide variety of diseases, however, it remains challenging to yield interpretable and actionable results. In this poster, we present novel computational methods that attempt to resolve this issues and demonstrate their use in several Alzheimer’s Disease datasets.Method: Two publicaly available datasets were used for this analysis: a post‐mortem single‐nucleus RNAseq dataset from the entorhinal cortex of Alzheimer’s Disease and non‐demented donors (Leng et al., 2021, Nature Neuroscience) and a post‐mortem single‐soma RNAseq dataset from the prefrontal cortex of Alzheimer’s Disease donors where tangle‐bearing neurons were sorted prior to sequencing (Otero‐Garcia et al., 2020, bioRxiv). In brief, our method, which we have named GeneFunnel, firstly optimizes filtering steps and statistical correctness (such as pseudobulking) to yield robust gene set enrichment results. Gene set enrichment is then used to guide prioritization of differentially expressed genes using hierarchial clustering and graph theory, focusing especially on the overlap of genes between gene sets.Result: Using several forms of visualization, we demonstrate how GeneFunnel can create a clear and succint overview of the processes involved in Alzheimer’s Disease. As the name implies, the results are made intuitively explorable, effectively facilitating a “funnel” that allows inspection at broad and narrow levels of depth.Conclusion: We show a novel approach to tackling large and complex expression datasets, demonstrating its utility in summarizing key molecular changes that take place in Alzheimer’s Disease.

12 March 2026 in Research Square
Verified
Preprint
Open access
PDF file
MFMartha Foiani
Martha Foiani
RNRaja Nirujogi
Raja Nirujogi
NWNaoto Watamura
Naoto Watamura
SBSumi Bez
Sumi Bez
ETEliona Tsefou
Eliona Tsefou
KDKaren Duff
Karen Duff
Tau pathology underlies a broad spectrum of neurodegenerative disorders, collectively termed tauopathies, yet these diseases exhibit striking heterogeneity in their biological mechanisms and clinical outcomes. The basis for this heterogeneity remains poorly understood. Here, we address this question using knock-in mouse models expressing two distinct frontotemporal dementia-associated tau mutations to define how different tau variants drive divergent pathogenic programs in vivo. We find that the two mutations give rise to fundamentally different trajectories of tau pathogenesis. One trajectory is marked by progressive tau hyperphosphorylation and cytoskeletal destabilization occurring in the absence of detectable tau seed formation. In contrast, an alternative trajectory is characterized by tau hypophosphorylation, early seed formation, and alterations in nucleotide metabolism and chromatin organization, without overt cytoskeletal disruption. With aging, tau in this latter pathway transitions to a hyperphosphorylated state and forms mature fibrillar aggregates. Genetic enhancement of β-amyloid selectively accelerates fibril formation, particularly in the model exhibiting early seeding. Together, these findings demonstrate that distinct tau mutations can engage separable pathogenic mechanisms, providing a biological framework for the heterogeneity observed across tauopathies and highlighting the need for mechanism-informed therapeutic strategies and patient stratification.

31 July 2026 in Science Advances
Verified
Journal Article
Open access
ETEliona Tsefou
Eliona Tsefou
SBSumi Bez
Sumi Bez
TBTimothy J. Y. Birkle
Timothy J. Y. Birkle
MFMartha Foiani
Martha Foiani
NWNaoto Watamura
Naoto Watamura
KDKaren E. Duff
Karen E. Duff
The accumulation of pathological four-repeat (4R) tau is central to several frontotemporal dementia (FTD) subtypes, but human neuronal models amenable to high-throughput screening of 4R tau–targeting therapies remain very limited. To address this, we developed induced pluripotent stem cell (iPSC)–derived i 3 Neuron (i 3 N) lines expressing >75% 4R tau, driven by FTD splice-shifting mutations (Ser 305 Asn; S305N or S305N/IVS10 + 3). These neurons develop hyperphosphorylated tau and demonstrate somatodendritic mislocalization. These i 3 N neurons develop endogenous seed-competent tau and present pentameric formyl thiophene acetic acid–(pFTAA)-positive tau assemblies after 28 days in culture. For scalable screening, we CRISPR-engineered an HiBiT luminescence tag at the endogenous MAPT locus into the S305N/IVS10 + 3 iPSC line, enabling precise quantification of tau levels and pharmacological responses. The model responded predictably to compounds affecting tau clearance, demonstrating its suitability for drug discovery. Overall, this i 3 N platform recapitulates key features of 4R tauopathy and provides a robust system to identify therapeutic modulators of pathological tau.